The Journal of Urology
Volume 181, Issue 4 , Pages 1606-1614 , April 2009

Prostate Specific Antigen Testing Among the Elderly—When To Stop?

  • Edward M. Schaeffer

      Affiliations

    • Department of Urology, The Johns Hopkins University School of Medicine, The James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, Maryland
    • Corresponding Author InformationCorrespondence: Department of Urology, Marburg 134, Johns Hopkins School of Medicine, 600 N. Wolfe St., Baltimore, Maryland 21287 (telephone: 410-502-2733; FAX: 410-955-0833)
    • Financial interest and/or other relationship with Covidien.
    • ,
  • H. Ballentine Carter

      Affiliations

    • Department of Urology, The Johns Hopkins University School of Medicine, The James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, Maryland
    • Nothing to disclose.
    • ,
  • Anna Kettermann

      Affiliations

    • Department of Urology, The Johns Hopkins University School of Medicine, The James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, Maryland
    • Nothing to disclose.
    • ,
  • Stacy Loeb

      Affiliations

    • Department of Urology, The Johns Hopkins University School of Medicine, The James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, Maryland
    • Nothing to disclose.
    • ,
  • Luigi Ferrucci

      Affiliations

    • Clinical Research Branch, National Institute on Aging, National Institutes of Health, Baltimore, Maryland
    • Nothing to disclose.
    • ,
  • Patricia Landis

      Affiliations

    • Department of Urology, The Johns Hopkins University School of Medicine, The James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, Maryland
    • Nothing to disclose.
    • ,
  • Bruce J. Trock

      Affiliations

    • Department of Urology, The Johns Hopkins University School of Medicine, The James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, Maryland
    • Nothing to disclose.
    • ,
  • E. Jeffrey Metter

      Affiliations

    • Clinical Research Branch, National Institute on Aging, National Institutes of Health, Baltimore, Maryland
    • Nothing to disclose.

Received 14 August 2008

References 

  1. Surveillance, Epidemiology, and End Results (SEER) Program. StatDatabase. 2007;
  2. Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst. 2002;94:981
  3. Cooperberg MR, Moul JW, Carroll PR. The changing face of prostate cancer. J Clin Oncol. 2005;23:8146
  4. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA. 2005;293:2095
  5. Sirovich BE, Schwartz LM, Woloshin S. Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence?. JAMA. 2003;289:1414
  6. Walter LC, Bertenthal D, Lindquist K, Konety BR. PSA screening among elderly men with limited life expectancies. JAMA. 2006;296:2336
  7. U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;149:185
  8. Merenstein D. A piece of my mind (Winners and losers). JAMA. 2004;291:15
  9. Lilja H, Ulmert D, Bjork T, Becker C, Serio AM, Nilsson JA, et al. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J Clin Oncol. 2007;25:431
  10. Shock NW, Greulich RC, Andres R, Arenberg D, Costa PT, Lakatta EG, et al. Normal human aging: The Baltimore Longitudinal Study of Aging. NIH Publication No. 84-2450. Washington, D. C: Government Printing Office; 1984;
  11. D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol. 2003;21:2163
  12. Boorjian SA, Blute ML. Surgical management of high risk prostate cancer: the Mayo Clinic experience. Urol Oncol. 2008;26:530
  13. Welch HG, Schwartz LM, Woloshin S. Prostate-specific antigen levels in the United States: implications of various definitions for abnormal. J Natl Cancer Inst. 2005;97:1132
  14. Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ, Crowley JJ, et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA. 2005;294:66
  15. Arias E. United States Life Tables. National Vital Statistics Reports. 2003;Vol 54:No 14 Hyattsville, MD: National Center for Health Statistics; 2006;http://www.cdc.gov/nchs/data/nvsr/nvsr54/nvsr54_14.pdfAccessed August 16, 2007
  16. AUA. Oncology From the American Urological Association: Prostate-Specific Antigen (PSA) Best Practice Policy. February 2000;Vol 14:No 2 http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines.cfmAccessed August 14, 2008
  17. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer Early Detection. http://www.nccn.org/professionals/physician_gls/PDF/prostate_detection.pdfAccessed August 14, 2008
  18. Smith RA, Cokkinides V, von Eschenbach AC, Levin B, Cohen C, Runowicz CD, et al. American Cancer Society guidelines for the early detection of cancer. CA Cancer J Clin. 2002;52:8
  19. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA. 1995;273:289
  20. Fall K, Garmo H, Andren O, Bill-Axelson A, Adolfsson J, Adami HO, et al. Prostate-specific antigen levels as a predictor of lethal prostate cancer. J Natl Cancer Inst. 2007;99:526

 Study received institutional review board approval.

 Supported by the Intramural Research Program of the National Institutes of Health, National Institute on Aging.

 See Editorial on page 1534.

 Editor's Note: This article is the first of 5 published in this issue for which category 1 CME credits can be earned. Instructions for obtaining credits are given with the questions on pages 1970 and 1971.

PII: S0022-5347(08)03280-1

doi: 10.1016/j.juro.2008.11.117

The Journal of Urology
Volume 181, Issue 4 , Pages 1606-1614 , April 2009

Article Tools

* Image Usage & Resolution